Advertisement

American Journal of Clinical Dermatology

, Volume 6, Issue 1, pp 1–11 | Cite as

Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus

Therapy In Practice

Abstract

Antimalarials have been used to treat cutaneous and systemic lupus erythematosus (LE) for decades. Although controlled studies comparing the efficacy of antimalarials versus placebo and other treatments are generally lacking, many case reports and series support the therapeutic efficacy of these agents in treating both LE-specific and -nonspecific skin lesions. Currently, the two most frequently used antimalarial agents are chloroquine and hydroxychloroquine. There may be a delay of weeks to months in the onset of therapeutic effects of antimalarials when treating LE. Smoking appears to inhibit the therapeutic efficacy of antimalarials when treating cutaneous LE. Antimalarials have been associated with a number of potentially serious adverse effects, including irreversible loss of vision. The aim of this review is to discuss the many facets of antimalarials that will help clinicians optimally utilize these agents when treating cutaneous LE.

Keywords

Systemic Lupus Erythematosus Chloroquine Hydroxychloroquine Quinacrine Antimalarial Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Payne JF. A postgraduate lecture on lupus erythematosus. Clin J 1894; 4: 223–9Google Scholar
  2. 2.
    Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: the Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 65–7Google Scholar
  3. 3.
    Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol Biopharm 1978; 16: 395–401PubMedGoogle Scholar
  4. 4.
    Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 1974; 3: 103–8PubMedCrossRefGoogle Scholar
  5. 5.
    McChesney EW, Rothfield NF. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7: 328–9Google Scholar
  6. 6.
    Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189: 425–7PubMedCrossRefGoogle Scholar
  7. 7.
    Lipsker D, Piette JC, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190: 257–8PubMedCrossRefGoogle Scholar
  8. 8.
    Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9: 92–5PubMedCrossRefGoogle Scholar
  9. 9.
    Koranda FC. Antimalarials. J Am Acad Dermatol 1981; 4: 650–5Google Scholar
  10. 10.
    Sjolin-Forsberg G, Berne B, Blixt C, et al. Chloroquine phosphate: a long-term follow up of drug concentration in skin suction blister fluid and plasma. Acta Derm Venereol 1993; 73: 426–9PubMedGoogle Scholar
  11. 11.
    Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985; 64: 285–95PubMedCrossRefGoogle Scholar
  12. 12.
    Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471–5PubMedCrossRefGoogle Scholar
  13. 13.
    Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis 1982; 8: 207–18PubMedGoogle Scholar
  14. 14.
    McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg 2001; 20: 14–26PubMedCrossRefGoogle Scholar
  15. 15.
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–4CrossRefGoogle Scholar
  16. 16.
    The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus’ erythematosus. Lupus 1997; 7: 80–5Google Scholar
  17. 17.
    Sontheimer RD, Provost TT. Cutaneous manifestations of lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 5th ed. Baltimore (MD): Williams & Wilkins, 1997: 569–23Google Scholar
  18. 18.
    Sontheimer RD, Thomas JR, Gilliam JM. Subacute cutaneous lupus erythematosus. Arch Dermatol 1979; 115: 1409–15PubMedCrossRefGoogle Scholar
  19. 19.
    Cardinali C, Caproni M, Baenacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus: the Italian experience. Lupus 2000; 9: 417–23PubMedCrossRefGoogle Scholar
  20. 20.
    Furner BB. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 1990; 29: 542–7PubMedCrossRefGoogle Scholar
  21. 21.
    Ruzicka T, Bieber T, Meurer M. Subacute cutaneous lupus erythematosus: clinical aspects, immunology and therapy. Wien Klin Wochenschr 1987; 99: 802–7PubMedGoogle Scholar
  22. 22.
    Jessop S, Whitelaw D, Jordan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001; 1: XXCD 002954Google Scholar
  23. 23.
    Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118: 412–6PubMedCrossRefGoogle Scholar
  24. 24.
    Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 1997; 24: 569–72PubMedGoogle Scholar
  25. 25.
    Morgan KW, Callen JP. Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 2001; 28: 129–32Google Scholar
  26. 26.
    Harvey S, Pineda R, Shore JW, et al. Hypertrophic discoid lupus erythematosus of conjunctiva. Am J Ophthalmol 1999; 127: 604–5CrossRefGoogle Scholar
  27. 27.
    Donzis PB, Insler MS, Buntin DM, et al. Discoid lupus erythematosus involving the eyelids. Am J Ophthalmol 1984; 98: 32–6PubMedCrossRefGoogle Scholar
  28. 28.
    Pock L, Petrovska P, Becvar R, et al. Verrucous form of chilblain lupus erytheto matosus. J Eur Acad Dermatol Venereol 2001; 15: 448–51PubMedCrossRefGoogle Scholar
  29. 29.
    Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33–51PubMedCrossRefGoogle Scholar
  30. 30.
    Werth V, Franks A. Treatment of discoid skin lesions with azathioprine. Arch Dermatol 1986; 122: 746–7PubMedCrossRefGoogle Scholar
  31. 31.
    Wallace DJ. Antimalarials: the “real” advance in lupus. Lupus 2001; 10: 385–7PubMedCrossRefGoogle Scholar
  32. 32.
    Wallace DJ. Antimalarial therapies. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 5th ed. Baltimore (MD): Williams & Wilkins, 1997: 1117–40Google Scholar
  33. 33.
    Rahman P, Gladmann DD, Urowitz MB. Efficacy of antimalarial therapy in cutaneous lupus in smokers versus non-smokers. J Rheumatol 1998; 25: 1716–9PubMedGoogle Scholar
  34. 34.
    Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42: 983–7PubMedCrossRefGoogle Scholar
  35. 35.
    Miller RG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990; 9: 125–35PubMedGoogle Scholar
  36. 36.
    Polet T. The effects of lysosomotrophic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes. J Cell Physiol 1985; 122: 415–23PubMedCrossRefGoogle Scholar
  37. 37.
    Wanwimolruk S, Wong SM, Coville PF, et al. Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol 1993; 36: 610–4PubMedCrossRefGoogle Scholar
  38. 38.
    Hardy CJ, Palmer BP, Muir KR, et al. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 1998; 57: 451–5PubMedCrossRefGoogle Scholar
  39. 39.
    Nagata C, Fujita S, Iwata H, et al. Systemic lupus erythematosus: a case-control epidemiologic study in Japan. Int J Dermatol 1995; 34: 333–7PubMedCrossRefGoogle Scholar
  40. 40.
    Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 243–63PubMedGoogle Scholar
  41. 41.
    Johansson E, Kanerva L, Niemi KM, et al. Diffuse soft tissue calcifications (calcinosis cutis) in patient with discoid lupus erythematosus. Clin Exp Dermatol 1988; 13: 193–6PubMedCrossRefGoogle Scholar
  42. 42.
    Marzano AV, Kolesnikova LV, Gasparini G, et al. Dystrophic calcinosis cutis in subacute cutaneous lupus. Dermatology 1999; 90: 90–2CrossRefGoogle Scholar
  43. 43.
    Wozniacka A, Robak E, Sysa-Jedrzejowska A, et al. The influence of chloroquine treatment on minimal erythema dose measurements in systemic lupus erythematosus patients [abstract]. J Invest Dermatol 2002; 3: 763Google Scholar
  44. 44.
    Nishijima C, Hatta N, Inaoki M, et al. Urticarial vasculitis in systemic lupus erythematosus: fair response to prednisolone/dapsone and persistent hypocomplementemia. Eur J Dermatol 1999; 9: 54–6PubMedGoogle Scholar
  45. 45.
    Malcangi G, Brandozzi G, Giangiacomi M, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003; 12: 63–6PubMedCrossRefGoogle Scholar
  46. 46.
    Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol 2000; 41: 234–7PubMedCrossRefGoogle Scholar
  47. 47.
    Krim E, Noblesse I, Beylot Barry M, et al. Bullous localization of a lupus erythematosus induced by radiotherapy. Ann Dermatol Venereol 2002; 129: 1307–9PubMedGoogle Scholar
  48. 48.
    48. Fowler Jr JF, Callen JP. Cutaneous mucinosis associated with lupus erythematosus. J Rheumatol 1984; 11: 380–3PubMedGoogle Scholar
  49. 49.
    Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus; a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033–41PubMedCrossRefGoogle Scholar
  50. 50.
    Fox JN, Klapman MH, Rowe L. Lupus profundus in children: treatment with hydroxychloroquine. J Am Acad Dermatol 1987; 16: 839–44PubMedCrossRefGoogle Scholar
  51. 51.
    Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 1993; 28: 634–70CrossRefGoogle Scholar
  52. 52.
    Magana-Garcia M. Antimalarials for children [letter]. J Am Acad Dermatol 1994; 3: 510CrossRefGoogle Scholar
  53. 53.
    Khamashta MA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus 1996; 5: S65–6PubMedCrossRefGoogle Scholar
  54. 54.
    Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double blind and placebo-controlled study. Lupus 2001; 10: 401–4PubMedCrossRefGoogle Scholar
  55. 55.
    Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2004; 50: 3056–7CrossRefGoogle Scholar
  56. 56.
    Tett SE, Cutler DJ, Day RO, et al. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26: 303PubMedCrossRefGoogle Scholar
  57. 57.
    Petri M. Thrombosis and systemic lupus erythematosus; the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191–3PubMedCrossRefGoogle Scholar
  58. 58.
    Rynes RI. Antimalarials: is re-evaluation needed? J Clin Rheumatol 1998; 4: 50–1PubMedCrossRefGoogle Scholar
  59. 59.
    Hobbs HE, Eadie SP, Somerville F. Ocular lesions after treatment with chloroquine. Br J Ophthalmol 1961; 45: 284–97PubMedCrossRefGoogle Scholar
  60. 60.
    Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 206–21PubMedCrossRefGoogle Scholar
  61. 61.
    Lozier JR, Friedlaender MH. Complications of antimalarial therapy. Int Ophthalmol Clin 1989; 29: 172–8PubMedCrossRefGoogle Scholar
  62. 62.
    Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482–6PubMedCrossRefGoogle Scholar
  63. 63.
    Mavrikakis I, Mavrikakis E. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Rheumatology 2004; 43: 1057–8PubMedCrossRefGoogle Scholar
  64. 64.
    Araiza-Casillas R, Cardenas F, Morales Y, et al. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13: 621CrossRefGoogle Scholar
  65. 65.
    Neubauer AS, Samari-Kermani K, Schaller U, et al. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 2003; 87: 902–8PubMedCrossRefGoogle Scholar
  66. 66.
    Pluenneke AC, Blomquist PH. Utility of red Amsler grid screening in a rheumatology clinic. J Rheumatol 2004; 31: 1754–5PubMedGoogle Scholar
  67. 67.
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723–31CrossRefGoogle Scholar
  68. 68.
    Sontheimer RD. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus. Arch Dermatol 2000; 136: 1044–9PubMedCrossRefGoogle Scholar
  69. 69.
    Trenholme GM, Carson PE. Therapy and prophylaxis of malaria. JAMA 1978; 240: 2293–5PubMedCrossRefGoogle Scholar
  70. 70.
    Custer RP. Aplastic anemia in soldiers treated with Atabrine (quinacrine). Am J Med Sci 1946; 212: 211–24PubMedGoogle Scholar
  71. 71.
    Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981; 20: 57–61PubMedCrossRefGoogle Scholar
  72. 72.
    Schmid I, Anasetti C, Petersen FB, et al. Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine. Blut 1990; 61: 52–4PubMedCrossRefGoogle Scholar
  73. 73.
    Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol 1985; 12: 863–5PubMedCrossRefGoogle Scholar
  74. 74.
    Evans RL, Khalid S, Kinney JL. Antimalarial psychosis revisited. Arch Dermatol 1984; 120: 765–7PubMedCrossRefGoogle Scholar
  75. 75.
    Genel F, Erermis S, Aksu G, et al. Quinacrine-induced psychiatric disturbances in a child with common variable immunodeficiency and chronic giardiasis. Hum Psychopharmacol 2002; 17: 357–9PubMedCrossRefGoogle Scholar
  76. 76.
    Tristano AG, Falcon L, Wilson M, et al. Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus. Rheum Int 2004; 24: 315–6CrossRefGoogle Scholar
  77. 77.
    Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. Acta Derm Venereol 1999; 79: 333PubMedCrossRefGoogle Scholar
  78. 78.
    Jimenez-Alonso J, Tercedor J, Reche I. Antimalarial drugs and pruritus in patients with lupus erythematosus [letter]. Acta Derm Venereol 2000; 80: 458PubMedGoogle Scholar
  79. 79.
    Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol 2004; 50: 650–1PubMedCrossRefGoogle Scholar
  80. 80.
    Litt JZ. Litt’s drug eruption manual. 9th ed. New York: Parthenon Publishing, 2003: 91Google Scholar
  81. 81.
    Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a re-examination. Semin Arthritis Rheum 1989; 18: 282–97PubMedCrossRefGoogle Scholar
  82. 82.
    Metayer I, Balguerie X, Courville P, et al. Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 2001; 128: 729–31PubMedGoogle Scholar
  83. 83.
    Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1231–3PubMedCrossRefGoogle Scholar
  84. 84.
    Verny C, Gennes C, Sebastien P, et al. Heart conduction disorders in long-term treatment with chloroquine: two new cases. Presse Med 1992; 21: 800–4PubMedGoogle Scholar
  85. 85.
    Physicians desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 3008Google Scholar
  86. 86.
    Physicians desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 2984Google Scholar
  87. 87.
    Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001; 19: 420–4PubMedCrossRefGoogle Scholar
  88. 88.
    Harris L, Downar E, Shaikh NA, et al. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiol 1988; 4: 295–300PubMedGoogle Scholar
  89. 89.
    Seidman P, Albertioni F, Beck O, et al. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 830–3CrossRefGoogle Scholar
  90. 90.
    McElnay JC, Sidahmed AM, D’Arcy PF. Examination of the chloroquine-kaolin drug absorption interaction using the buccal partitioning model. J Clin Hosp Pharm 1982; 7: 269–73PubMedGoogle Scholar
  91. 91.
    Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987; 27: 813–6PubMedGoogle Scholar
  92. 92.
    Algharably N, Owler D, Lamb JF. The rate of uptake of cardiac glycosides into human cultured cells and the effects of chloroquine on it. Biochem Pharmacol 1986; 35: 3571–81PubMedCrossRefGoogle Scholar
  93. 93.
    Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 1996; 712: 179–89PubMedCrossRefGoogle Scholar
  94. 94.
    Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol 2000; 42: 645–52PubMedGoogle Scholar
  95. 95.
    Makin AJ, Wendon J, Fitt S, et al. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994; 35: 569–70PubMedCrossRefGoogle Scholar
  96. 96.
    Fries JF, Singh G, Lenert L, et al. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611–9PubMedCrossRefGoogle Scholar
  97. 97.
    Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Opthalmol 2002; 133: 649–56CrossRefGoogle Scholar
  98. 98.
    Fox R, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5: S31–6PubMedCrossRefGoogle Scholar
  99. 99.
    Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221–5PubMedCrossRefGoogle Scholar
  100. 100.
    Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27: 2927–31PubMedGoogle Scholar
  101. 101.
    Desta M, Tadesse A, Gebre N, et al. Controlled trial of hydroxychloroquine in schizophrenia. J Clin Psychopharmacol 2002; 22: 507–10PubMedCrossRefGoogle Scholar
  102. 102.
    Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11: 71–81PubMedCrossRefGoogle Scholar
  103. 103.
    Landewe RB, Miltenburg AM, Breedveld FC, et al. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353–7PubMedGoogle Scholar
  104. 104.
    Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med 1983; 18: 19–24CrossRefGoogle Scholar
  105. 105.
    Sjolin-Forsberg G, Berne B, Eggelte TA, et al. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995; 75: 228–31PubMedGoogle Scholar
  106. 106.
    Olczyk K, Drozdz M, Kucharz E, et al. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus. Med Interne 1984; 22: 221–5PubMedGoogle Scholar
  107. 107.
    Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5: S4–S10PubMedCrossRefGoogle Scholar
  108. 108.
    Ruzicka T, Printz M. Arachidonic acid metabolism in guinea pig skin: effects of chloroquine. Agents Actions 1982; 12: 527–9PubMedCrossRefGoogle Scholar
  109. 109.
    Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 803–8PubMedGoogle Scholar
  110. 110.
    Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003; 139: 50–4PubMedCrossRefGoogle Scholar
  111. 111.
    Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148: 353–6PubMedCrossRefGoogle Scholar
  112. 112.
    Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12: 50–2PubMedGoogle Scholar
  113. 113.
    Gerdsen R, Wenzel I, Uerlich M, et al. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology 2002; 205: 416–8PubMedCrossRefGoogle Scholar
  114. 114.
    Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43(11): 1383–5CrossRefGoogle Scholar
  115. 115.
    Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51(3): 407–10PubMedCrossRefGoogle Scholar
  116. 116.
    Hall RP, Lawley TJ, Smith HR, et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165–70PubMedGoogle Scholar
  117. 117.
    Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapyWidespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35: 313–5PubMedCrossRefGoogle Scholar
  118. 118.
    Neri R, Mosca M, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. Lupus 1999; 8: 240–3PubMedCrossRefGoogle Scholar
  119. 119.
    Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991; 24: 49–52PubMedCrossRefGoogle Scholar
  120. 120.
    Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513–8PubMedCrossRefGoogle Scholar
  121. 121.
    Arbiser JL, Moschella SL. Clofazimine: A revive of its medical uses and mechanfor isms of action. J Am Acad Dermatol 1995; 32: 241–7PubMedCrossRefGoogle Scholar
  122. 122.
    Tsokos GC, Caughman SW, Kleppel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1985; 121: 1323–5PubMedCrossRefGoogle Scholar
  123. 123.
    Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechresistant anisms. Rheumatol Int 1998; 18: 59–62PubMedCrossRefGoogle Scholar
  124. 124.
    Bohm I, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194: 307–8PubMedCrossRefGoogle Scholar
  125. 125.
    Peter RU, Ruzicka T. Cyclosporin A in the therapy of inflammatory dermatoses. Hautarzt 1992; 43: 687–4PubMedGoogle Scholar
  126. 126.
    Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986; 115: 211–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Department of DermatologyMedical University of LodzKrzemienieckaPoland
  2. 2.Rutland Skin CenterRutlandUSA

Personalised recommendations